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Although oncogene-targeted therapy often elicits
profound initial tumor responses in patients, re-
sponses are generally incomplete because some
tumor cells survive initial therapy as residual disease
that enables eventual acquired resistance. The
mechanisms underlying tumor cell adaptation and
survival during initial therapy are incompletely under-
stood. Here, through the study of EGFR mutant lung
adenocarcinoma, we show that NF-kB signaling
is rapidly engaged upon initial EGFR inhibitor treat-
ment to promote tumor cell survival and residual
disease. EGFR oncogene inhibition induced an
EGFR-TRAF2-RIP1-IKK complex that stimulated an
NF-kB-mediated transcriptional survival program.
The direct NF-kB inhibitor PBS-1086 suppressed
this adaptive survival program and increased the
magnitude and duration of initial EGFR inhibitor
response in multiple NSCLC models, including a pa-
tient-derived xenograft. These findings unveil NF-kB
activation as a critical adaptive survival mechanism
engaged by EGFR oncogene inhibition and provide
rationale for EGFR and NF-kB co-inhibition to elimi-
nate residual diseaseandenhancepatient responses.
INTRODUCTION
Epidermal growth factor receptor (EGFR) mutant NSCLC is a
paradigm-defining model of the success and limitations of tar-
geted cancer therapy. Activating mutations in EGFR are present
in approximately 10%–35% of NSCLC patients (D’Angelo et al.,
2011). Although the EGFR tyrosine kinase inhibitors (TKIs) erloti-98 Cell Reports 11, 98–110, April 7, 2015 ª2015 The Authorsnib, gefitinib, and afatinib are approved as first-line therapy in
advanced-stage EGFR mutant NSCLC patients, resistance is a
major challenge. Approximately 20%–30% of patients exhibit
innate resistance and fail to respond to initial treatment, and
98% of patients who have an initial EGFR TKI response exhibit
an incomplete response (Mok et al., 2009; Zhou et al., 2011).
This incomplete therapy response results in residual disease
that enables the emergence of acquired resistance in patients,
often a lethal event. Although many mechanisms of either innate
or acquired resistance have been deciphered (Bivona et al.,
2011; Engelman et al., 2007; Ercan et al., 2012; Ng et al., 2012;
Ohashi et al., 2012, 2013; Sequist et al., 2011; Takezawa et al.,
2012; Turke et al., 2010; Yu et al., 2013; Zhang et al., 2012),
themolecular basis of incomplete response and residual disease
during initial EGFR TKI therapy is poorly understood. Filling this
knowledge gap is essential to identify therapeutic strategies to
combat tumor cell adaptation and survival during initial treat-
ment and induce complete responses in patients.
Prior work uncovered a cancer cell population (termed drug-
tolerant persisters) that withstood initial treatment via an
IGF1R-mediated epigenetic program that could be reversed
pharmacologically with chromatin-directed or IGF1R-targeted
therapy (Sharma et al., 2010). Subsequent clinical trials did
not show a significant effect of either chromatin-directed or
IGF1R-targeted therapy on response to concurrent EGFR kinase
inhibitor treatment in NSCLC patients (Goldberg et al., 2012;
Ramalingam et al., 2011). Although this hypothesis remains
promising, additional studies are required. Other work exploring
initial response to targeted therapy in cancer cells showed
that EGFR inhibition provokes STAT3 survival signaling (Lee
et al., 2014). The precise molecular mechanism underlying this
EGFR inhibitor-induced STAT3 signaling remains incompletely
understood.
Here, we further investigated signaling events that occur in
response to EGFR oncogene inhibition in NSCLC cells to enable
Figure 1. Adaptive NF-kB Activation in
Response to EGFR Oncogene Inhibition in
NSCLC
(A) FDG-PET computed tomography (CT) imaging
of the patient’s thorax with metastatic EGFR
mutant NSCLC (indicated by the white arrow) prior
to treatment with erlotinib and post-erlotinib with
residual disease present is shown. Scale bar,
2 cm.
(B) Representative IHC staining for the indicated
proteins demonstrating p-STAT3 and RELA nu-
clear localization (red arrows) as well as EGFR
L858R, p-EGFR, and p-ERK in tumors resected
from PDX mice treated with vehicle or erlotinib
(25 mg/kg/day) for 48 hr. Scale bar, 20 mm. Per-
centage of cells positive for nuclear p-STAT3 and
RELA (mean ± SEM) are indicated.
(C) Quantitation of nuclear p-STAT3 and nuclear
RELA in EGFR L858R mutant PDX tumors treated
with vehicle or erlotinib (mean ± SEM) is shown.
*p < 0.05, ***p < 0.001 as determined by two-tailed
unpaired t test.
(D and E) HCC827 and 11-18 cells were treated
with erlotinib (100 nM) for the indicated period of
time, and activity of the EGFR pathway was
monitored by western blot. V, vehicle-treated
controls. GAPDH was used as a loading control.
(F and G) HCC827 and 11-18 cells were treated
with erlotinib (100 nM) or afatinib (100 nM) for the
indicated periods of time, and nuclear and cyto-
solic fractions were separated to show the trans-
location of the NF-kB subunit RELA to the nucleus.
Lamin B1 is a marker of nuclear extraction. HSP60
is a marker of cytosolic extraction.
(H and I) Quantitative real-time PCR analysis of
indicated NF-kB target genes in (H) HCC827 and
(I) 11-18 cells in response to vehicle, erlotinib,
afatinib, or imatinib treatment for 12 hr (mean ±
SEM) is shown. *p < 0.05 compared to vehicle-
treated cells by Bonferroni multiple comparisons
ANOVA test. See also Figure S1.their adaptation and survival during initial therapy and thereby
promote residual disease. Although we previously found that
NF-kB promotes innate EGFR TKI resistance (Bivona et al.,
2011), in this study we explored the distinct hypothesis that
NF-kB activation might be triggered by initial EGFR TKI treat-
ment as an adaptive event to promote NSCLC cell survival and
residual disease, thus limiting EGFR inhibitor efficacy.
RESULTS
EGFR Oncogene Inhibition Triggers NF-kB Activation in
NSCLC Models
We explored whether NF-kB was activated in tumor cells ob-
tained at the time of residual disease in the setting of an initial
incomplete tumor response to EGFR TKImonotherapy. AlthoughCell Reports 11, 98patient tumor specimens obtained at re-
sidual disease after an initial response to
EGFR TKI monotherapy are rare, as sur-
gical resection for metastatic disease isuncommon, we had the opportunity to generate and study a pa-
tient-derived tumor xenograft (PDX) obtained from a patient with
oligometastatic EGFR mutant NSCLC treated with erlotinib. This
patient uncharacteristically underwent surgical resection of re-
sidual disease after an incomplete response to initial erlotinib
therapy, which was discontinued prior to surgery (Figure 1A).
The residual disease NSCLC specimen resected from this pa-
tient had the identical EGFR L858R mutation detected in the
pre-treatment tumor by a clinical DNA-sequencing assay, and
it had no evidence of the EGFR T790M resistance mutation or
other established oncogenic mutations by whole-exome deep
sequencing (mean coverage depth 1003, data not shown).
Immunohistochemical (IHC) staining of the resected tumor
confirmed expression of EGFR L858R, p-EGFR, and p-ERK in
the tumor cells, indicating oncogenic EGFR signaling in the–110, April 7, 2015 ª2015 The Authors 99
tumor (Figure S1A). The p-EGFR and p-ERK expression was
consistent with the clinical course of the patient, as the patient
was off of EGFR TKI at the time of surgery. We investigated
NF-kB activation status and that of STAT3 in the tumor using
RELA and p-STAT3 antibodies in IHC studies in the resected tu-
mor specimen. We found minimal RELA or p-STAT3 nuclear
expression in the patient tumor specimen (Figure S1A), suggest-
ing that these pathways were not significantly engaged in the
absence of EGFR TKI in the patient (Figure S1A).
We treated mice bearing this PDX tumor with erlotinib (or
vehicle) and assessed the effects of treatment on signaling in
the tumor after 48 hr. Tumors from vehicle-treated mice were
representative of the primary patient resected tumor specimen,
exhibiting expression of EGFR L858R, p-EGFR, and p-ERK
and minimal RELA or p-STAT3 nuclear expression (Figures 1B
and S1A). Erlotinib treatment of these mice led to decreased
levels of p-EGFR, p-ERK, and p-AKT (Figures 1B and S1B).
We observed a 2-fold increase in nuclear p-STAT3 in PDX tu-
mors treated with erlotinib (Figures 1B and 1C), consistent with
the STAT3 activation observed in EGFRmutant NSCLC cell lines
treated with an EGFR TKI (Lee et al., 2014). Strikingly, we found
that erlotinib treatment resulted in a 10-fold increase in nuclear
RELA expression in the tumor cells, which is indicative of
NF-kB activation (O’ Reilly et al., 2009; Figures 1B and 1C).
Thus, erlotinib treatment suppressed EGFR and canonical
downstream MEK-ERK and AKT signaling while concurrently
activating NF-kB and STAT3.
We used an established transgenic murine model of EGFR
mutant (EGFR L858R) NSCLC that recapitulates human
EGFR mutant NSCLC (Politi et al., 2006) to further explore
the link between NF-kB activation and residual disease on
EGFR TKI therapy. EGFR mutant NSCLCs in these transgenic
mice initially regressed upon erlotinib treatment, and then
developed acquired erlotinib resistance after several months
(Politi et al., 2010). This observation suggests that some tumor
cells survive initial erlotinib exposure as residual disease that
eventually grows to form a resistant tumor. To assess if NF-
kB is activated in residual tumor cells that persist following
initial erlotinib treatment, we treated EGFR L858R tumor-
bearing mice with erlotinib for 7 days and harvested lung tu-
mors representing residual disease on EGFR TKI therapy to
assess for evidence of NF-kB activation. Increased nuclear
RELA expression that is indicative of increased NF-kB activity
(O’ Reilly et al., 2009) was observed in tumors harvested from
mice treated with erlotinib (Figures S1C–S1E). These findings
suggest that NF-kB activity is increased in tumor cells that
persist through initial EGFR oncogene inhibition as residual
disease in the in vivo and immunocompetent tumor microenvi-
ronment. The findings in both the PDX and transgenic EGFR
mutant NSCLC residual disease tumors suggest that NF-kB
might be triggered by EGFR TKI treatment to promote tumor
cell survival and residual disease.
We used human EGFR mutant NSCLC cellular models to
further investigate EGFR TKI-induced NF-kB activation. Using
five different human EGFR mutant NSCLC cell line models
(HCC827 EGFR exon19 deletion, 11-18 EGFR L858R, H3255
EGFR L858R, PC9 exon19 deletion, and H1975 EGFR L858R/
T790M), we found that EGFR TKI treatment rapidly suppressed100 Cell Reports 11, 98–110, April 7, 2015 ª2015 The AuthorsAKT and MAPK signaling (Figures 1D and 1E), as expected
(Gong et al., 2007). In contrast, NF-kB was immediately hyper-
activated upon erlotinib or afatinib treatment (Figures 1F–1I and
S1F–S1H; Raskatov et al., 2012; Sun et al., 1994). This early
activation of NF-kB was specific to EGFR oncogene inhibition,
as the treatment of cells with the non-EGFR TKI imatinib did
not impact transcription of NF-kB target genes (Figures 1H
and 1I). H1975 NSCLC cells harboring the EGFR T790M erloti-
nib-resistance mutation exhibited increased RELA nuclear
localization specifically upon treatment with the EGFR inhibitor
afatinib that has activity against EGFR T790M, but not with er-
lotinib that does not (Figure S1H). Inhibition of the EML4-ALK
oncogenic fusion protein with the ALK inhibitor crizotinib also
failed to induce NF-kB activation in H3122 EML4-ALK-positive
NSCLC cells (Figure S1I). We found that NF-kB activation was
present in the subpopulation of EGFR mutant HCC827 NSCLC
cells that persisted during initial EGFR TKI therapy, representing
residual disease (Figure S1J). These persistent tumor cells ex-
hibited decreased p-EGFR, p-ERK, and p-AKT levels, indicating
that canonical MEK-ERK and AKT signaling remained inhibited
as NF-kB was specifically activated. The findings indicate that
EGFR oncogene inhibition promotes rapid and adaptive hyper-
activation of NF-kB in EGFR mutant NSCLC, and they suggest
that this heightened NF-kB signaling may limit initial EGFR TKI
response.
EGFR Oncogene Inhibition Induces
TRAF2 Ubiquitination and Activation of an
NF-kB-Activating Complex
Next, we studied the mechanism by which NF-kB is activated
by EGFR oncogene inhibition. Activation of canonical NF-kB
signaling involves assembly of a TRAF2-RIP1 signaling com-
plex via ubiquitination events initiated at an upstream receptor
(Ea et al., 2006). TRAF2 ubiquitination and RIP1 association
leads to IKK recruitment and activation, phosphorylation and
degradation of IkB, and NF-kB (RELA) nuclear translocation
(Hayden and Ghosh, 2008). We hypothesized that EGFR onco-
gene inhibition might promote immediate ubiquitination of
proteins that drive NF-kB signaling. To identify ubiquitination
events that might contribute to NF-kB activation in the context
of EGFR inhibition, we performed a global enrichment of
ubiquitinated proteins followed by mass spectrometry analysis
on proteins harvested from HCC827 cells treated with vehicle
or erlotinib. These studies revealed that the top-scoring ubiqui-
tination event in erlotinib-treated cells was increased ubiquiti-
nation of TRAF2 (Table 1), an established TRAF2 and NF-kB-
activating event (Mahul-Mellier et al., 2012). We confirmed
that treatment of HCC827 cells with either erlotinib or afatinib
induced TRAF2 K63-linked ubiquitination (Figure 2A). We
extended these findings to an additional EGFR mutant NSCLC
cell line, confirming that afatinib treatment induced TRAF2 K63-
linked ubiquitination in H1975 cells (Figure S2A). These studies
uncover early and dynamic regulation of ubiquitin-modifying
events that may modulate response to EGFR-targeted therapy
in NSCLC.
K63-linked TRAF2 ubiquitination is essential for RIP1 activa-
tion and subsequent activation of IKKb/g and NF-kB (Alvarez
et al., 2010; Ea et al., 2006; Li et al., 2009; Mahul-Mellier et al.,
Table 1. Ubiquitination Events Increased by Erlotinib Treatment in Human EGFR-Mutant NSCLC Cells
Peptide Protein Description Z Score Erl/DMSO
FQDHVKTCGK(gl) Q12933 TRAF2 (TNF receptor-associated factor 2) 1.94
SKHSEDVNVK(gl)VSNAQSVTSER O60669 MOT2 (monocarboxylate transporter 2) 1.31
WGK(gl)QDGGEGHVGTVR Q86YT6 MIB1 (E3 ubiquitin-protein ligase MIB1) 1.22
FLLGYFPWDSTK(gl)EER Q8TC07 TBC15 (TBC1 domain family member 15) 1.06
HIYYITGETK(gl)DQVANSAFVER P07900 HS90A (heat shock protein HSP 90-alpha) 1.05
SDALETLGFLNHYQMK(gl)NPNGPYPYTLK P14866 HNRPL (heterogeneous nuclear ribonucleoprotein L) 1.04
WLTLSEVMKLLK(gl) Q8IUC4 RHPN2 (rhophilin-2 jhomo sapiens) 0.99
SKASLEK(gl)AGK P53985 MOT1 (monocarboxylate transporter 1) 0.97
YALTGDEVK(gl)K P62701 RS4X (40S ribosomal protein S4, X isoform) 0.90
ERPPNPIEFLASYLLK(gl)NK Q9C005 DPY30 (protein dpy-30 homolog) 0.86
SIQLDGLVWGASK(gl)LVPVGYGIR P29692 EF1D (elongation factor 1-delta) 0.78
QLMTLENK(gl)LK Q7L7X3 TAOK1 (serine/threonine-protein kinase TAO1) 0.75
TYVDPHTYEDPNQAVLK(gl)FTTEIHPSCVTR P29317 EPHA2(ephrin type-A receptor 2) 0.61
The top protein peptides with a statistically significant increase in ubiquitination (Z score > 0.5) in erlotinib-treated samples compared to vehicle-
treated samples ranked by Z score (n = 3 for each condition). UniProt identification of the protein identified is indicated.2012). Overexpressed RIP1 can associate with EGFR in breast
cancer and glioma cells (Habib et al., 2001; Puliyappadamba
et al., 2013). Given that we uncovered increased TRAF2 ubiqui-
tination upon EGFR oncogene inhibition, we hypothesized that
EGFR TKI treatment might promote assembly and activation
(via ubiquitination) of a signaling complex containing TRAF2,
RIP1, and EGFR that activates IKK and downstream NF-kB
signaling. Through co-immunoprecipitation experiments, we
found that EGFR associates with TRAF2 and RIP1 in HCC827
EGFR mutant cells (Figure 2B). The formation of this TRAF2-
RIP1-EGFR complexwas enhanced by EGFR TKI treatment (Fig-
ure 2B). Increased association of RIP1 and IKKb with EGFR was
observed upon either erlotinib or afatinib treatment in both
HCC827 and 11-18 EGFRmutant NSCLC cell lines (Figure S2B),
but only upon treatment with the EGFR T790M inhibitor afatinib
in erlotinib-resistant H1975 cells (Figure S2C).
Attempts to detect this NF-kB-activating complex in vivo in
the PDX model were unsuccessful, perhaps because detecting
protein-protein associations is more challenging in vivo where
both tumor cells and contaminating normal cells are present
and can obscure detection of relevant interactions occurring
specifically in tumor cells. Hence, it remains unclear whether
the complex we detected in patient-derived cell lines is present
in vivo. Nevertheless, our collective findings indicate that forma-
tion of the NF-kB signaling complex is dynamically enhanced by
EGFR oncogene inhibition in several human EGFR mutant
NSCLC in vitro models. Using genetic knockdown experiments
in multiple NSCLC cell lines, we found that this NF-kB signaling
complex was essential for EGFR TKI-induced NF-kB activation,
as RIP1 and TRAF2 were each required for maximal induction of
p-IKKa/b and NF-kB target gene expression by EGFR TKI treat-
ment (Figures 2C, 2D, and S2D–S2F). Lastly, using a genetically
controlled system of primary immortalized human bronchial
epithelial cells (BEAS-2B) (Lonardo et al., 2002), we further
found that the presence of oncogenic EGFR was critical for for-
mation of this NF-kB signaling complex upon EGFR TKI treat-
ment (Figure 2E).Direct Pharmacologic NF-kB Inhibition Overrides EGFR
TKI-Induced NF-kB Activation and Suppresses the
Emergence of EGFR TKI Therapy Resistance
We next investigated the effects of pharmacologic inhibition of
NF-kB in the context of EGFR TKI treatment. Our prior studies
showed that NF-kB activation in EGFRmutant NSCLC cells sup-
presses EGFR TKI-induced apoptosis, which can be reversed by
genetic knockdown of RELA (Bivona et al., 2011). An obstacle to
clinical translation is that pharmacologic inhibitors of NF-kB
signaling clinically developed to date do not target NF-kB
directly, but rather do so indirectly by targeting either IKK or
the proteasome. These indirect NF-kB inhibitors exhibit non-
specific effects and limited therapeutic window in patients (Per-
kins, 2012).
We took an alternative approach to credential a direct pharma-
cologic inhibitor of NF-kB for potential use in combination with
an EGFR TKI in NSCLC patients. We tested PBS-1086 that
acts as a specific inhibitor of RELA/B DNA binding (Figure S3A;
Fabre et al., 2012). We conducted several studies to validate
PBS-1086 as a potent and selective NF-kB inhibitor. We profiled
the effects of PBS-1086 onDNA binding by RELA (p65) and other
common transcription factors in nuclear extracts using a tran-
scription factor DNA-binding assay (Renard et al., 2001), and
we found that PBS-1086 blocks RELA DNA binding (Figure S3B;
Table S1). By gene set enrichment analysis (GSEA) (Mootha
et al., 2003; Subramanian et al., 2005), we found PBS-1086 treat-
ment specifically suppressed the expression of canonical NF-kB
target genes and gene sets, but did not modulate expression of
genes regulated by other common transcription factors (Table
S2). We verified that PBS-1086 inhibits NF-kB transcriptional
activity in 11-18 cells using an established NF-kB activation re-
porter assay (Figure 3A; Aoki and Kao, 1997). Next, we profiled
the biochemical effects of PBS-1086, alone and combined with
EGFR TKI, in EGFR mutant NSCLC cell lines (Figure 3B). PBS-
1086 treatment of myeloma cells leads to decreased levels of
nuclear RELA (Fabre et al., 2012), as non-DNA-bound RELA un-
dergoes nuclear export (Harhaj and Sun, 1999). We observedCell Reports 11, 98–110, April 7, 2015 ª2015 The Authors 101
Figure 2. EGFR-TRAF2-NF-kB-Activating
Complex Forms in Response to EGFR
Oncogene Inhibition in NSCLC
(A) Activation of the NF-kB signalosome was
demonstrated by an ubiquitination assay of the
TRAF2 protein. HCC827 cells were transfected
with HA-Ubiquitin K63 plasmid and treated with
erlotinib (100 nM) or afatinib (100 nM) for 30 min.
Subsequently, cell lysates were used for endoge-
nous immunoprecipitation of TRAF2 to determine
its ubiquitination status by western blot.
(B) Immunoprecipitation of endogenous EGFR
from HCC827 cells treated with erlotinib at the
indicated time points, indicating the assembly of
essential components of NF-kB signaling, is
shown.
(C and D) Western blot analysis of EGFR and
NF-kB signaling in HCC827 cells treated with
RIP1 and TRAF2-specific small interfering RNAs
(siRNAs) ± erlotinib is shown.
(E) Co-immunoprecipitation of NF-kB signal-
osome with exogenously expressed mutant EGFR
upon erlotinib (100 nM) treatment of BEAS-2B
human bronchial epithelial cells. All results shown
represent three independent experiments. See
also Figure S2.that in each of three EGFR mutant NSCLC cell lines, PBS-1086
treatment reduced nuclear RELA levels (Figure 3B). PBS-1086
treatment blunted the RELA nuclear localization induced by
EGFR TKI treatment in each cell line (Figure 3B). EGFR TKI-
induced phosphorylation of IkBa was not affected by PBS-
1086 treatment, indicating that the drug inhibits NF-kB signaling
at the level of REL nuclear function and does not inhibit upstream
components of the NF-kB pathway (Figure 3B). These data vali-
date PBS-1086 as a potent and specific inhibitor of NF-kB tran-
scriptional activity in human NSCLC cells.
We explored the impact of PBS-1086 treatment on EGFR TKI
efficacy in EGFR mutant NSCLC models. The 11-18 cells were
relatively less sensitive to EGFR TKI treatment (erlotinib IC50 
1.5 mM) compared to HCC827 or H3255 cell lines (erlotinib IC50
 10 and  100 nM, respectively). The 11-18 cells did not ex-
press resistance-conferring lesions, associated with acquired
resistance in patients, and exhibited high basal NF-kB activity102 Cell Reports 11, 98–110, April 7, 2015 ª2015 The Authorsthat was further enhanced by EGFR TKI
treatment (Figures 1E–1G and 3B). We
used these cells as a model of NF-kB-
mediated residual disease on EGFR TKI
treatment, and we found that treatment
of 11-18 cells or tumor xenografts with
PBS-1086 enhanced erlotinib response
(Figures 3C, 3D, and S3C). This enhanced
response was associated with the induc-
tion of apoptosis upon PBS-1086 and
erlotinib polytherapy (Figures 3E and
3F). The effects of PBS-1086 treatment
occurred predominantly through REL (A,
B) inhibition, as we observed minimal ad-
ditive effect of PBS-1086 treatment on er-lotinib sensitivity in 11-18 cells in which we genetically silenced
RELA or RELB (Figure S3D). Exogenous expression of a consti-
tutively active RELA rescued the effects of PBS-1086 treatment
on erlotinib sensitivity (Figure S3D). These findings show the syn-
thetic lethality of combined EGFR and NF-kB (REL) inhibition
(with PBS-1086), suggesting a polytherapy to eliminate residual
disease.
Next, we explored the effects of pharmacologic NF-kB inhibi-
tion in EGFR mutant cell lines that model the common clinical
scenario in which a patient has a substantial, though incomplete,
EGFR TKI response. We reasoned that HCC827 and H1975
cells, which are relatively sensitive to EGFR TKI monotherapy,
would allow us to test if NF-kB inhibition with PBS-1086 might
decrease the presence of residual disease and the emergence
of acquired EGFR TKI resistance. We derived a panel of
HCC827 sub-clones with acquired erlotinib resistance through
prolonged, continuous erlotinib treatment and profiled NF-kB
transcriptional activity (Aoki and Kao, 1997).We observed NF-kB
hyperactivation in 50% (6 of 12) of the resistance sub-clones
(Figure S3E). Erlotinib-resistant cells exhibited increased associ-
ation of IKKbwith EGFR, indicating that these cells with acquired
erlotinib resistance harbored increased formation of the NF-kB-
activating complex (Figure S3F). Erlotinib-resistant sub-clones
that exhibited NF-kB activation did not harbor the EGFR
T790M resistance mutation or MET overexpression (data not
shown). To test whether NF-kB activity was necessary for ac-
quired EGFR TKI resistance, we treated the resistant sub-clones
with PBS-1086 alone and in combination with erlotinib. Treat-
ment with PBS-1086 and erlotinib reversed acquired erlotinib
resistance specifically in the cellular models with NF-kB hyper-
activation (Figure S3G).
Given that these findings indicated that NF-kB activation may
promote the survival of cells during initial EGFR TKI treatment,
which drives acquired resistance, we reasoned that initial treat-
ment with PBS-1086 might suppress the development of
acquired EGFR TKI resistance. PBS-1086 treatment in combina-
tion with erlotinib suppressed the emergence of acquired resis-
tance in HCC827 cells both in vitro (Figure 3G) and in vivo
(Figure 3H). These effects were phenocopied in H1975 cells
with EGFR L858R/T790M, in which we similarly found that
PBS-1086 treatment suppressed the emergence of acquired
afatinib resistance in vitro (Figure 3I). These findings suggest
that early activation of NF-kB is required for the survival of a sub-
set of cells that subsequently emerge to promote acquired EGFR
TKI resistance. Pharmacologic blockade of NF-kB with PBS-
1086 may overcome and prevent the development of acquired
resistance in EGFR mutant NSCLC.
IL6 Is a Critical NF-kB Target Gene Induced by EGFR TKI
Treatment that Underlies NF-kB-Mediated Survival
during EGFR TKI Therapy
We explored the downstream targets through which activated
NF-kB suppresses apoptosis and promotes survival during
EGFR TKI therapy. As the NF-kB target gene repertoire is
context specific, we used an unbiased approach to define by
whole-transcriptome sequencing (RNA sequencing [RNA-seq])
a transcriptional profile of NF-kB activation in EGFR mutant
NSCLC cells (GEO accession number GSE65420). We geneti-
cally inhibited NF-kB signaling through expression of a non-
phosphorylatable form of IkB (IkBSR) (Jiang and Clemens,
2006). Conversely, we genetically activated NF-kB signaling
through expression of a constitutively active form of RELA
(RELA S536E) (Hu et al., 2004), which promoted erlotinib resis-
tance (Figure S3D). Using these tools, we defined a set of
NF-kB target genes that, through differential expression anal-
ysis of the transcriptome data, were both activated by the
expression of RELA S536E and suppressed by IkBSR expres-
sion, and that were established direct transcriptional targets
of NF-kB in the ENCODE dataset (Bernstein et al., 2012;
Figure S4A).
We then determined which of these NF-kB target genes was
differentially regulated by erlotinib, PBS-1086, or the combina-
tion. We established the genetic signature of adaptive NF-kB
activation induced upon EGFR oncogene inhibition by identifying
the genes whose expression was increased by erlotinib treat-ment and also decreased by PBS-1086 in the presence of
erlotinib. This signature of EGFR TKI-induced NF-kB output con-
sisted of 36NF-kB target genes, including established regulators
of NF-kB signaling and cell survival such as TNFAIP3, BIRC3,
and IL6 (Figures 4A and S4A). We confirmed that the expression
of a subset of the genes in this signature was increased upon
treatment with multiple EGFR TKIs and decreased with PBS-
1086 in multiple EGFR mutant NSCLC cell lines (Figures S4B
and S4C). These data uncover the NF-kB-regulated genetic
signature and components of the adaptive response to EGFR
oncogene inhibition in NSCLC cells.
Next, we investigated whether individual components of the
NF-kB output signature promoted EGFR TKI resistance. IL6
was a component of this EGFR TKI-induced, adaptive NF-kB-
mediated transcriptional program. As a secreted factor, IL6
could act in an autocrine/paracrine manner to promote survival
of a subset of tumor cells in the bulk population during initial ther-
apy. IL6 was consistently and significantly increased by EGFR
TKI treatment in two distinct EGFR mutant NSCLC model (Fig-
ures 1H and 1I), and was recently implicated as a mediator of
EGFR TKI-induced STAT3 activation (Lee et al., 2014). We
confirmed that EGFR TKI treatment increased IL6 mRNA and
secreted IL6 protein levels in 11-18 cells (Figures 4B and 4C).
This induction of IL6 was suppressed by PBS-1086 (Figures
4B, 4C, S4B, and S4C), suggesting that NF-kB promotes IL6
expression induced by EGFR inhibitor treatment. We found
that exogenous expression of IL6 rescued the effects of PBS-
1086 treatment on erlotinib sensitivity in 11-18 cells (Figures
4D and 4E), while genetic silencing of IL6was sufficient to sensi-
tize 11-18 cells to erlotinib treatment (Figure 4F). These data
reveal that IL6 may operate downstream of NF-kB in the adap-
tive response to EGFR oncogene inhibition in NSCLC.
Given that IL6 promotes JAK2/STAT3 activation (Berishaj
et al., 2007), we hypothesized that NF-kB may be required for
EGFR TKI-induced STAT3 activation. We found that PBS-1086
inhibited erlotinib-induced STAT3 activation in three EGFR
mutant NSCLC cell lines (Figures 4G, S4D, and S4E), as well
as in HCC827 tumor xenografts (Figures S4F and S4G). We
tested whether direct JAK2 inhibition with a specific inhibitor,
ruxolitinib (Quinta´s-Cardama et al., 2010; Tefferi et al., 2011),
could reverse the pro-survival effects of IL6 induced by EGFR
TKI treatment. Co-treatment with erlotinib and ruxolitinib over-
came IL6-mediated erlotinib resistance in 11-18 cells (Figures
4D, 4E, and 4G). IL6 functioned downstream of NF-kB, as we
observed that PBS-1086 treatment suppressed the induction
of p-STAT3 by EGFR TKI treatment in the absence, but not the
presence, of exogenous IL6 (Figure 4G). Inhibition of IL6
signaling by JAK2 inhibitor treatment was required to suppress
p-STAT3 in the presence of exogenous IL6 (Figure 4G). The
data show that EGFR TKI treatment induces adaptive NF-kB
activation that drives a transcriptional program that includes up-
regulation of IL6-STAT3 signaling. Although IL6-STAT3 signaling
has been implicated in survival and resistance in some cancers,
including EGFR mutant NSCLC, our work reveals that this
pathway functions downstream of NF-kB during the early adap-
tive response to EGFR oncogene inhibition in NSCLC (Bromberg
et al., 1999; Gao et al., 2007; Kim et al., 2012; Lee et al., 2014;
Timofeeva et al., 2013).Cell Reports 11, 98–110, April 7, 2015 ª2015 The Authors 103
Figure 3. Pharmacologic Direct NF-kB Inhibition with PBS-1086 Enhances EGFR TKI Response and Suppresses the Emergence of Acquired
Resistance in EGFR Mutant NSCLC Models
(A) NF-kB transcriptional activation activity in 11-18 cells treated as indicated and measured by luciferase reporter assay (mean ± SEM) is shown. **p < 0.01,
***p < 0.001 as determined by Bonferroni multiple comparisons ANOVA test.
(B) Nuclear/cytoplasmic fractionation and western blot analysis of the indicated proteins in 11-18, HCC827, and H1975 cells treated as indicated are shown.
(C) Drug sensitivity asmeasured by half-maximal inhibitory concentration (IC50) of erlotinib (mean ±SEM) in 11-18 cells treated with vehicle or 5.0 mMPBS-1086 is
shown. **p < 0.01 as determined by two-tailed unpaired t test.
(D) Mean change in tumor volume (±SEM) of 11-18 EGFRmutant NSCLC tumor xenografts over a 10-day period after treatment of mice with the drugs indicated.
A minimum of ten tumors were evaluated per treatment group. The percentage of tumors with regression is shown under treatment cohort, revealing that
combined erlotinib + PBS-1086 treatment (using the monotherapy dose of each drug in the combination) induces significantly more tumor regressions than
monotherapy. ***p < 0.001 in comparison to each other treatment group by Bonferroni multiple comparisons ANOVA test.
(legend continued on next page)
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Direct Pharmacologic Inhibition of NF-kBwith PBS-1086
Enhances Response to EGFR TKI Treatment and
Suppresses Residual Disease In Vivo
We used the EGFRmutant PDX tumor model we generated, and
in which we observed induction of NF-kB activity upon EGFR TKI
treatment, to assess whether combined treatment with PBS-
1086 and erlotinib was more effective than EGFR TKI monother-
apy. As these tumors were derived from a patient with residual
disease following erlotinib treatment (Figure 1A), they did not
respond to erlotinib monotherapy (Figures 5A and S5A; Table
S3). In contrast, treatment of mice with PBS-1086 combined
with erlotinib promoted significant tumor responses, indicating
that PBS-1086 could overcome NF-kB-mediated survival of
the tumor cells in this residual disease NSCLC specimen (Figures
5A and S5A; Table S3).
Erlotinib monotherapy induced RELA nuclear translocation
and transcriptional upregulation of NF-kB target genes (Figures
1B, 5B, 5C, and S5B). IL6 was most significantly increased
with erlotinib treatment (Figure S5B), consistent with our
in vitro findings (Figure 4). Co-treatment with PBS-1086 and er-
lotinib reversed the RELA nuclear translocation and induction
of NF-kB target gene expression (Figures 5B, 5C, and S5B),
consistent with the tumor response to this combination therapy.
This improved tumor and signaling response was associated
with increased tumor cell apoptosis and decreased proliferation
(Figures 5B and 5C). The data demonstrate the potential for com-
bined PBS-1086 and EGFR TKI treatment to overcome residual
disease.
We also studied the EGFR mutant transgenic murine model
that represents the common clinical scenario in which a patient
has a profound initial response to EGFR TKI therapy. We found
that these mice often exhibit a partial response to EGFR TKI
monotherapy, as do most patients, and that some tumor cells
persisting during this incomplete response and residual disease
had increased nuclear RELA (Figure S1). We treated these mice
with erlotinib andPBS-1086andcompared the response to treat-
mentwith erlotinib or PBS-1086monotherapy. Treatment ofmice
with the combination of erlotinib and PBS-1086 reversed the ef-
fects of erlotinib on RELA nuclear localization and increased tu-
mor response (Figures 5D and S5C–S5E). These data suggest
that PBS-1086 treatment suppressed EGFR mutant tumor cell
persistence during initial EGFR TKI therapy within the native tu-
mor microenvironment and intact host immune system. Animals
treatedwith PBS-1086 either alone or combinedwith erlotinib ex-
hibited no significant toxicity at the efficacious doses we tested
(data not shown). These in vivo data provide further evidence
that adaptive NF-kB activation in tumor cells exposed to an(E) Effect of combined erlotinib + PBS-1086 treatment (using the monotherapy do
marker (cleaved PARP) in the erlotinib-resistant 11-18 cells is shown.
(F) Relative caspase activity in 11-18 cells upon treatment as indicated (mean ±
shown. ***p < 0.001 by Bonferroni multiple comparisons ANOVA test.
(G) Comparison of time to the development of acquired resistance of HCC827 cell
median time to treatment resistance.
(H) Growth of HCC827 tumor xenografts (mean ± SEM) treated as indicated ove
combination. p value was determined by linear regression analysis.
(I) Comparison of time to the development of acquired resistance of H1975 cells
median time to treatment resistance. See also Figure S3 and Tables S1 and S2.EGFR TKI enables incomplete response and residual disease
that can be overcome by NF-kB inhibition with PBS-1086, lead-
ing to improved EGFR TKI response.
DISCUSSION
We provide insight into the adaptive signaling events that occur
in response to targeted cancer therapy to enable tumor cells to
survive initial oncogene-targeted therapy. NF-kB hyperactiva-
tion in response to EGFR oncogene inhibition may counteract
the effects of oncogene withdrawal in the tumor cell population,
enabling tumor cell persistence manifesting as an incomplete tu-
mor response and residual disease. This surviving tumor cell
population with NF-kB hyperactivation may ultimately promote
acquired resistance, potentially in conjunction with additional
resistance-conferring alterations, such as EGFR T790M or
MET amplification.
Our findings have important implications for overcoming
EGFR TKI resistance in NSCLC patients, offering an alternative
approach to combat the emergence of resistance. Most clinical
strategies aimed at overcoming EGFR TKI resistance in NSCLC
have focused on counteracting the effects of individual genetic
alterations present in drug-resistant tumors in patients who
have already developed resistance (Koeppen et al., 2014; Miller
et al., 2012; Solca et al., 2012; Walter et al., 2013). Our findings
suggest that, even when individual resistance lesions such as
EGFR T790M are inhibited, adaptive activation of NF-kBmay still
drive tumor cell survival. This adaptive NF-kB activation and
consequent tumor cell survival can be suppressed by NF-kB in-
hibition. Our findings provide mechanistic rationale for upfront
combination therapy with PBS-1086 and an approved or
emerging EGFR TKI to minimize or eliminate residual disease
and thereby enhance response magnitude and duration in
patients.
EXPERIMENTAL PROCEDURES
Cell Lines and Assays
Cell lines were acquired from ATCC and as previously described (Bivona
et al., 2011; Zhang et al., 2012). All drugs were purchased from Selleck Chem-
icals. PBS-1086 was provided by rel-MD. The 72-hr viability assays were
performed as previously described (Zhang et al., 2012). Each assay consisted
of six replicate wells and was repeated at least twice in independent
experiments.
Animal Studies
The 11–18 tumor xenografts were generated as previously described (Bivona
et al., 2011). For genetically engineered mouse model (GEMM) studies, malese of each drug in combination) on EGFR signaling components and apoptosis
SEM, where the monotherapy dose of each drug was used in combination) is
s treated as indicated. p values were determined by log rank test comparing the
r a 28-day period. The monotherapy dose for each drug also was used in the
treated as indicated. p values were determined by log rank test comparing the
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Figure 4. An NF-kB Transcriptional Survival
Program Triggered by EGFR Oncogene Inhi-
bition Promotes Tumor Cell Survival and
Resistance
(A) Supervised hierarchical clustering of NF-kB-
regulated gene expression changes in 11-18 cells
treated as indicated based on RNA-seq analysis.
The analysis revealed a genetic signature of the NF-
kB-mediated adaptive response to EGFR TKI
treatment that consisted of a core set of NF-kB
target genes induced by erlotinib and, in turn,
suppressed by NF-kB inhibition.
(B) RNA-seq analysis of 11-18 cells demonstrating
induction or inhibition of IL6 expression by
pharmacologic and genetic manipulation (mean ±
SEM) is shown. ***p < 0.001 by Bonferroni multiple
comparisons ANOVA test.
(C) ELISA demonstrating the effect of the indicated
drug treatments on soluble IL6 protein expression
in 11-18 cells treated as indicated (mean ± SEM) is
shown. *p < 0.05 by Bonferroni multiple compari-
sons ANOVA test. The monotherapy dose for each
drug also was used in the combination.
(D) Drug sensitivity as measured by half-maximal
inhibitory concentration (IC50) of erlotinib (mean ±
SEM) in 11-18 cells transfected with empty
vector (EV) or an IL6-expressing construct (IL6)
and treated with the indicated drug combinations
is shown. The PBS-1086 + Ruxolitinib combina-
tion condition used the indicated monotherapy
dose for each drug. *p < 0.05, **p < 0.01 as
determined by Bonferroni multiple comparisons
ANOVA test.
(E) Relative mRNA expression of IL6 as determined
by quantitative real-time PCR of 11-18 cells
transfected with control siRNA, IL6 siRNA, empty
vector (EV), or IL6 overexpression construct (IL6)
treated with PBS-1086 (mean ± SEM) is shown.
**p < 0.01, ***p < 0.001 as determined by two-tailed
unpaired test.
(F) Drug sensitivity as measured by half-maximal
inhibitory concentration (IC50) of erlotinib (mean ±
SEM) in 11-18 cells treated with IL6-specific or
control siRNAs is shown. ***p < 0.001 as deter-
mined by two-tailed unpaired test.
(G) Western blots show the effects of the indicated
drug treatments on STAT3 activation (phosphory-
lation) in stably transfected 11-18 (EV) and 11-18
(IL6) cell lines. See also Figure S4.and female mice of the desired genotype were treated with doxycycline at 6–
8 weeks of age, and tumor-bearing mice were treated with the indicated
compounds at 16–18 weeks of age. Mice were genotyped and treated
with doxycycline to induce lung adenocarcinoma formation as previously
described (Politi et al., 2006). Mice were randomized to receive vehicle, erlo-
tinib, PBS-1086, or erlotinib + PBS-1086 (minimum of three mice per treat-
ment group) daily for 7 days by intraperitoneal (i.p.) injection. For generation
of PDX, informed consent was obtained from the patient as per an open Uni-
versity of California, San Francisco (UCSF) Institutional Review Board (IRB)-106 Cell Reports 11, 98–110, April 7, 2015 ª2015 The Authorsapproved protocol. Tumors were allowed to grow
until they reached a minimum volume of 200 mm3,
at which point mice were treated with combina-
tions of erlotinib and/or PBS-1086 as described
above. All animal studies were conducted inaccordance with the UCSF Institutional Animal Care and Use Committee
(IACUC).
Protein Studies
For western blotting, cells were scraped and lysed in lysis buffer (50 mM
Tris$HCl [pH 8.0], 150 mM sodium chloride, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1% Triton X-100, and 5 mM EDTA containing protease and phospha-
tase inhibitors [Roche Diagnostics]). All western blot results shown represent
three independent experiments. Where indicated, nuclear and cytosolic
Figure 5. Direct Pharmacologic Inhibition of
NF-kB with PBS-1086 Effectively Targets
Residual Disease to Enhance Response to
EGFR TKI Treatment In Vivo
(A) Mean change (±SEM) in tumor volume of PDX
treated with the indicated drugs for 10 days is
shown. ***p < 0.001 compared to all other groups
by Bonferroni multiple comparisons ANOVA test.
The monotherapy dose for each drug also was
used in the combination.
(B and C) Representative IHC staining and
quantitation (mean ± SEM) for RELA, p-STAT3,
cleaved-caspase 3 (CC3), Ki67, or EGFR-L858R
performed on PDX tumors treated as indicated for
48 hr are shown. Scale bar, 20 mm. **p < 0.01,
***p < 0.001 as determined by Bonferroni multiple
comparisons ANOVA test.
(D) Mean change in tumor volume (±SEM) is
shown, as determined byMRI of CC10-rtTA; TetO-
EGFRL858R transgenic mice treated with doxycy-
cline for 10 weeks (d0) followed by treatment
with the indicated drugs for 7 days (d7). *p < 0.05 in
comparison to erlotinib monotherapy-treated
mice by two-tailed unpaired t test. The mono-
therapy dose for each drug also was used in the
combination. See also Figure S5 and Table S3.fractionation were performed as previously described (Fabre et al., 2012). For
immunoprecipitations, cell lysates were incubated overnight at 4C with the
antibodies of interest. Immune complexes were precipitated with Protein-G
and the beads were washed with RIPA buffer. Immunoprecipitated proteinsCell Reports 11, 98–were separated in a 4%–15% SDS-PAGE and
transferred onto a nitrocellulose membrane (Bio-
Rad). Membranes were blocked with 5% fetal
bovine serum (FBS) in Tris-buffered saline (TBS)
containing 0.1% Tween and incubated with the
appropriate antibodies.
Raw mass spectrometry data were analyzed
using the MaxQuant software package (version
1.3.0.5) (Cox and Mann, 2008). Data were
matched to the SwissProt human reference pro-
tein database. Data were searched against a
concatenated database containing all sequences
in both forward and reverse directions, with
reverse hits indicating the false discovery rate of
identifications. The data were filtered to obtain a
peptide, protein, and site-level false discovery
rate of 0.01. The minimum peptide length was
seven amino acids. Results were matched be-
tween runs with a time window of 2 min for tech-
nical duplicates. A Z score was calculated to
assess the statistical probability of an increase
in ubiquitination of a given peptide in the erloti-
nib-treated samples compared to the DMSO
(vehicle)-treated samples, and a decrease in ubiq-
uitination in the DMSO-treated samples compared
to the erlotinib-treated samples. Only peptides
with a Z score >0.5 in both directions were consid-
ered significant.
RNA Analysis
RNA-seq was performed in triplicate for each
treatment condition on the Illumina Hi-Seq 2000
using paired-end 100-bp reads as previouslydescribed (Li and Dewey, 2011; Lin et al., 2014). Differential expression anal-
ysis between sets of conditions was performed using DESeq (Anders and
Huber, 2010) and as previously described (Lin et al., 2014). The qPCRwas per-
formed on the QuantStudio 12K Flex Real-Time QPCR System using Taqman110, April 7, 2015 ª2015 The Authors 107
probes (Applied Biosystems, Life Technologies) and analyzed as previously
described (Lin et al., 2014).
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